
Click on each section you wish to purchase
Click on add to cart to add all the sections in shopping cart
Click on the cart to proceed to payment
Click on Checkout to complete the final checkout
Executive Summary
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2018" provides an overview of Acute and Sub-Acute Bursitis clinical trials scenario. This report provides top line data relating to the clinical trials on Acute and Sub-Acute Bursitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Acute and Sub-Acute Bursitis Therapeutics Clinical Trials 29
Clinical Trial Profile Snapshots 31
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 50
Contact Us 51
Source 51
List of Figures
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 10
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 13
Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2018* 15
Acute and Sub-Acute Bursitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Acute and Sub-Acute Bursitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2018* 19
Acute and Sub-Acute Bursitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Acute and Sub-Acute Bursitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
GlobalData Methodology 50
List of Tables
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Region, 2018* 7
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 10
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 13
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2018* 16
Acute and Sub-Acute Bursitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Acute and Sub-Acute Bursitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Acute and Sub-Acute Bursitis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2018* 20
Acute and Sub-Acute Bursitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Acute and Sub-Acute Bursitis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Acute and Sub-Acute Bursitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Acute and Sub-Acute Bursitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Perrigo Company Plc
Mylan NV
Mimer Medical AB
MEDRx Co Ltd
IBSA Institut Biochimique SA
Dr. Reddy's Laboratories Ltd
Conventia Medical LLP
Bluefish Pharmaceuticals AB
Acute and Sub-Acute Bursitis Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Acute and Sub-Acute Bursitis, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
For Regular updates on our latest research reports
Compare